Chia-Hui Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Chia-Hui Luo has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alan Chuan-Ying Lai
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
2 shared publications - Chun-Chou Tsai
Institute of Immunology, Chung Shan Medical University, Taichung, Taiwan
2 shared publications - Ethan Ja-Chen Chung
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
2 shared publications - Wei-Yu Chen
Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan
2 shared publications - Ya-Jen Chang
Institute of Biomedical Sciences, Academia Sinica, Taipei City, Taiwan
2 shared publications - Yu-Shan Chang
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
2 shared publications
Latest Publications
- Open Access
- 10 September 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (17)
Staphylococcus aureus exacerbates dermal IL-33/ILC2 axis activation through evoking RIPK3/MLKL-mediated necroptosis of dry skin
- 10 September 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (17)
Open AccessStaphylococcus aureus exacerbates dermal IL-33/ILC2 axis activation through evoking RIPK3/MLKL-mediated necroptosis of dry skin
- Open Access
- 6 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (6)
Staphylococcus aureus exacerbates dermal IL-33/ILC2 axis activation through evoking RIPK3/MLKL-mediated necroptosis of dry skin
Atopic dermatitis (AD) is a persistent skin disease typified by symptoms of dry skin and recurrent eczema. Patients with AD are at heightened risk for Staphylococcus aureus infection. Group 2 innate lymphoid cells (ILC2s) are mainly activated by epithelial cell–derived cytokines IL-33 and involved in the pathogenesis of AD. However, little is known about the effect of skin delipidization on the epithelial cell–derived cytokines and dermal ILC2s in AD. In our study, we investigated the mechanism by which S . aureus infection modulates and exacerbates the pathogenesis of dry skin, leading to type 2 inflammation in the context of innate immunity. In vivo, we found that S . aureus infection aggravated delipidization-induced dermal IL-33 release and dermal ILC2 accumulation, which exacerbated skin inflammation. We also noticed that Il33 fl/fl K14 cre mice and Tlr2 –/– mice exhibited attenuated skin inflammation. In vitro, treatment with necroptosis inhibitors reduced IL-33 release from S . aureus –infected keratinocytes. Mechanistically, we observed an increase in the necroptosis-associated kinases, MLKL and RIPK3, in S . aureus –infected mice, indicating that IL-33 release was associated with necroptotic cell death responses. Our results reveal that S . aureus infection–elicited keratinocyte necroptosis contributes to IL-33–mediated type 2 inflammation, which exacerbates the pathogenesis of dry skin.
- 6 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (6)
Open AccessStaphylococcus aureus exacerbates dermal IL-33/ILC2 axis activation through evoking RIPK3/MLKL-mediated necroptosis of dry skin
Atopic dermatitis (AD) is a persistent skin disease typified by symptoms of dry skin and recurrent eczema. Patients with AD are at heightened risk for Staphylococcus aureus infection. Group 2 innate lymphoid cells (ILC2s) are mainly activated by epithelial cell–derived cytokines IL-33 and involved in the pathogenesis of AD. However, little is known about the effect of skin delipidization on the epithelial cell–derived cytokines and dermal ILC2s in AD. In our study, we investigated the mechanism by which S . aureus infection modulates and exacerbates the pathogenesis of dry skin, leading to type 2 inflammation in the context of innate immunity. In vivo, we found that S . aureus infection aggravated delipidization-induced dermal IL-33 release and dermal ILC2 accumulation, which exacerbated skin inflammation. We also noticed that Il33 fl/fl K14 cre mice and Tlr2 –/– mice exhibited attenuated skin inflammation. In vitro, treatment with necroptosis inhibitors reduced IL-33 release from S . aureus –infected keratinocytes. Mechanistically, we observed an increase in the necroptosis-associated kinases, MLKL and RIPK3, in S . aureus –infected mice, indicating that IL-33 release was associated with necroptotic cell death responses. Our results reveal that S . aureus infection–elicited keratinocyte necroptosis contributes to IL-33–mediated type 2 inflammation, which exacerbates the pathogenesis of dry skin.